Cargando…

Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma

BACKGROUND: To evaluate a treatment protocol with repeated transarterial-chemoembolisation (TACE) downsizing before MR-guided laser-induced interstitial thermotherapy (LITT) using different chemotherapeutic combinations in patients with unresectable colorectal cancer (CRC) liver metastases. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogl, T J, Jost, A, Nour-Eldin, N A, Mack, M G, Zangos, S, Naguib, N N N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314788/
https://www.ncbi.nlm.nih.gov/pubmed/22382689
http://dx.doi.org/10.1038/bjc.2012.69
_version_ 1782228139080941568
author Vogl, T J
Jost, A
Nour-Eldin, N A
Mack, M G
Zangos, S
Naguib, N N N
author_facet Vogl, T J
Jost, A
Nour-Eldin, N A
Mack, M G
Zangos, S
Naguib, N N N
author_sort Vogl, T J
collection PubMed
description BACKGROUND: To evaluate a treatment protocol with repeated transarterial-chemoembolisation (TACE) downsizing before MR-guided laser-induced interstitial thermotherapy (LITT) using different chemotherapeutic combinations in patients with unresectable colorectal cancer (CRC) liver metastases. METHODS: Two hundred and twenty-four patients were included in the current study. Transarterial-chemoembolisation (mean 3.4 sessions per patient) was performed as a downsizing treatment to meet the LITT requirements (number⩽5, diameter <5 cm). The intra-arterial protocol consisted of either Irinotecan and Mitomycin (n=77), Gemcitabine and Mitomycin (n=49) or Mitomycin alone (n=98) in addition to Lipiodol and Embocept in all patients. Post TACE, all patients underwent LITT (mean 2.2 sessions per patient). RESULTS: Overall, TACE resulted in a mean reduction in diameter of the target lesions of 21.4%. The median time to progression was 8 months, calculated from the start of therapy and the median local tumour control rate was 7.5 months, calculated as of therapy completion. Median survival of patients calculated from the beginning of TACE was 23 months (range 4–110 months), in patients treated with Irinotecan and Mitomycin the median was 22.5 months, Gemcitabine and Mitomycin 23 months and Mitomycin only 24 months with a statistically significant difference between the groups (P<0.01). CONCLUSION: Repeated TACE offers adequate downsizing of CRC liver metastases to allow further treatment with LITT. The combined treatment illustrates substantial survival rates and high local tumour control with statistically significant differences between the three protocols used. Further randomised trials addressing the current study results are required.
format Online
Article
Text
id pubmed-3314788
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-33147882013-03-27 Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma Vogl, T J Jost, A Nour-Eldin, N A Mack, M G Zangos, S Naguib, N N N Br J Cancer Clinical Study BACKGROUND: To evaluate a treatment protocol with repeated transarterial-chemoembolisation (TACE) downsizing before MR-guided laser-induced interstitial thermotherapy (LITT) using different chemotherapeutic combinations in patients with unresectable colorectal cancer (CRC) liver metastases. METHODS: Two hundred and twenty-four patients were included in the current study. Transarterial-chemoembolisation (mean 3.4 sessions per patient) was performed as a downsizing treatment to meet the LITT requirements (number⩽5, diameter <5 cm). The intra-arterial protocol consisted of either Irinotecan and Mitomycin (n=77), Gemcitabine and Mitomycin (n=49) or Mitomycin alone (n=98) in addition to Lipiodol and Embocept in all patients. Post TACE, all patients underwent LITT (mean 2.2 sessions per patient). RESULTS: Overall, TACE resulted in a mean reduction in diameter of the target lesions of 21.4%. The median time to progression was 8 months, calculated from the start of therapy and the median local tumour control rate was 7.5 months, calculated as of therapy completion. Median survival of patients calculated from the beginning of TACE was 23 months (range 4–110 months), in patients treated with Irinotecan and Mitomycin the median was 22.5 months, Gemcitabine and Mitomycin 23 months and Mitomycin only 24 months with a statistically significant difference between the groups (P<0.01). CONCLUSION: Repeated TACE offers adequate downsizing of CRC liver metastases to allow further treatment with LITT. The combined treatment illustrates substantial survival rates and high local tumour control with statistically significant differences between the three protocols used. Further randomised trials addressing the current study results are required. Nature Publishing Group 2012-03-27 2012-03-01 /pmc/articles/PMC3314788/ /pubmed/22382689 http://dx.doi.org/10.1038/bjc.2012.69 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Vogl, T J
Jost, A
Nour-Eldin, N A
Mack, M G
Zangos, S
Naguib, N N N
Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma
title Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma
title_full Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma
title_fullStr Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma
title_full_unstemmed Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma
title_short Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma
title_sort repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by mr-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314788/
https://www.ncbi.nlm.nih.gov/pubmed/22382689
http://dx.doi.org/10.1038/bjc.2012.69
work_keys_str_mv AT vogltj repeatedtransarterialchemoembolisationusingdifferentchemotherapeuticdrugcombinationsfollowedbymrguidedlaserinducedthermotherapyinpatientswithlivermetastasesofcolorectalcarcinoma
AT josta repeatedtransarterialchemoembolisationusingdifferentchemotherapeuticdrugcombinationsfollowedbymrguidedlaserinducedthermotherapyinpatientswithlivermetastasesofcolorectalcarcinoma
AT noureldinna repeatedtransarterialchemoembolisationusingdifferentchemotherapeuticdrugcombinationsfollowedbymrguidedlaserinducedthermotherapyinpatientswithlivermetastasesofcolorectalcarcinoma
AT mackmg repeatedtransarterialchemoembolisationusingdifferentchemotherapeuticdrugcombinationsfollowedbymrguidedlaserinducedthermotherapyinpatientswithlivermetastasesofcolorectalcarcinoma
AT zangoss repeatedtransarterialchemoembolisationusingdifferentchemotherapeuticdrugcombinationsfollowedbymrguidedlaserinducedthermotherapyinpatientswithlivermetastasesofcolorectalcarcinoma
AT naguibnnn repeatedtransarterialchemoembolisationusingdifferentchemotherapeuticdrugcombinationsfollowedbymrguidedlaserinducedthermotherapyinpatientswithlivermetastasesofcolorectalcarcinoma